Asian Journal of Pharmaceutical Research and Health Care

Open Access Open Access  Restricted Access Subscription Access

Determinants of Parasite Clearance Time among Plasmodium knowlesi Patients in Malaysia


Affiliations
1 Quality Management of Medicine, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur − 50300, Malaysia
2 Department of Pharmacy, Hospital Kuala Lipis, 27200 Kuala Lipis, Pahang, Malaysia, Malaysia
 

Plasmodium (P.) knowlesi infection was only recently discovered in 2004, and since then the number of cases has increased each year. As such, there is still a need to understand the clinical management of P. knowlesi infection to ensure control of the disease. Therefore, this work was performed to determine factors that affect the clinical outcome of P. knowlesi infected patients. A cross-sectional study from 2012 to 2016 was conducted in Hospital Kuala Lipis, Pahang, Malaysia. The main clinical outcome was parasite clearance. A total of 72 P. knowlesi patients were included, which were mostly male (n=56, 77.80%), with a mean age of 37.39±14.61 years. Fifty-six patients (77.80%) were prescribed with artemisinin-based antimalarial following diagnosis, while the remaining patients (n=16, 22.20%) were treated with chloroquine. The length for parasite clearance of P. knowlesi was 4(4-5) days [(median (IQR)]. Factors that affect the primary outcome of the study (>4 days for parasite clearance) was then determined. A multivariate logistic regression demonstrated that significant predictors of parasite clearance were initial parasite levels and number of symptoms (χ2=11.97, df(69), P=0.003). Those with an initial parasite count of > 2 400/uL were 4.8 times more likely to take > 4 days for parasite clearance (P=0.02). Having < 4 symptoms increased the odds of > 4 days for parasite clearance by 0.14 times (P=0.02). This study shows the need to closely monitor patients with higher initial parasite counts (> 2400/uL) and patients with > 4 symptoms associated with P. knowlesi infection, to ensure appropriate treatment is administered.


Keywords

Clinical Outcome, Malaria, Parasite, Plasmodium knowlesi
User
Notifications
Font Size

  • World Health Organization. World Malaria Report 2015. Geneva: World Health Organization; 2015 [update 2015 Dec]. Data cited 2020 Jan 10. Available from: https://www.who.int/malaria/publications/world-malaria-report-2015/report/en/.

  • Singh B, Sung LK, Matusop A, Radhakrishnan A, Shamsul SS, Cox-Singh J, et al. A large focus of naturally acquired Plasmodium knowlesi infections in human beings. The Lancet. 2004; 363(9414):1017-1024. https://doi.org/10.1016/S0140-6736(04)15836-4.

  • Barber BE, Grigg MJ, William T, Yeo TW, Anstey NM. The treatment of Plasmodium knowlesi malaria. Trends in Parasitology. 2016; 33:242-253. https://doi.org/10.1016/j.pt.2016.09.002. PMid: 27707609.

  • Barber BE, William T, Grigg MJ, Menon J, Auburn S, et al.A prospective comparative study of knowlesi, falciparum, and vivaxmalaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy. Clinical Infectious Disease. 2012; 56(3):383-397. https://doi.org/10.1093/cid/cis902. PMid: 23087389.

  • William T, Menon J, Rajahram G, Chan L, Ma G, Donaldson S, et al. Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia. Emerging Infectious Disease. 2011; 17(7):1248. https://doi.org/10.3201/eid1707.101017. PMid: 21762579.

  • Rajahram GS, Barber BE, William T, Grigg MJ, Menon J, Yeo TW, et al. Falling Plasmodium knowlesi malaria death rate among adults despite rising incidence, Sabah, Malaysia, 2010-2014. Emerging Infectious Disease. 2016; 22(1):41. https://doi.org/10.3201/eid2201.151305. PMid: 26690736, PMCid: PMC4696710.

  • Singh B, Daneshvar C. Human infections and detection of Plasmodium knowlesi. Clinical Microbiology Reviews. 2013; 26(2):165-184. https://doi.org/10.1128/CMR.0007912. PMid: 23554413, PMCid: PMC3623376.

  • Ministry of Health, Malaysia. Management of guidelines of malaria in Malaysia. Vector Borne Disease Sector, Disease Control Division, Ministry of Health, Putrajaya Malaysia; 2014 [cited 2020 Jan 10]. Available from: file:///C:/Users/USER/Downloads/MANAGEMENT_GUIDELINES_OF_MALARIA _IN_MALAYSIA.pdf1_%20(1).pdf.

  • Vadivelan M, Dutta T. Recent advances in the management of Plasmodium knowlesi infection. Tropical Parasitology. 2014; 4(1):31-34. https://doi.org/10.4103/2229-5070.129158. PMid: 24754024, PMCid: PMC3992799.

  • Imai N, White MT, Ghani AC, Drakeley CJ. Transmission and control of Plasmodium knowlesi: A mathematical modelling study. PLoS Neglected Tropical Diseases. 2014; 8:1-9. https://doi.org/10.1371/journal.pntd.0002978. PMid: 25058400, PMCid: PMC4109903.

  • Ooi CH, Bujang MA, Bakar TM, Ngui R, Lim YA. Over two decades of Plasmodium knowlesi infections in Sarawak: Trend and forecast. ActaTropica. 2017; 176:83-90. https://doi.org/10.1016/j.actatropica.2017.07.027. PMid: 28768148.

  • Rajahram GS, Barber BE, William T, Menon J, Anstey NM, Yeo TW. Deaths due to Plasmodium knowlesi malaria in Sabah, Malaysia: association with reporting as Plasmodium malariae and delayed parenteral artesunate. Malaria Journal. 2012; 11(1):284. https://doi.org/10.1186/14752875-11-284. PMid: 22905799, PMCid: PMC3472242.

  • Ariffin NM, Islahudin F, Makmor-Bakry M, Kumolosasi E, Mudin RN, Shamsudin UK, et al. Pattern of antimalarial drug use in Malaysia. Indian Journal of Pharmaceutical Sciences. 2016; 78(3):423-427. https://doi.org/10.4172/pharmaceutical-sciences.1000135.

  • Li T, Sheng J, Li W, Zhang X, Yu H, Chen X, Zhang J, et al. A new computational model for human thyroid cancer enhances the preoperative diagnostic efficacy. Oncotarget. 2015; 6(29):28463. https://doi.org/10.18632/oncotarget.4691. PMid: 26325368, PMCid: PMC4695072.

  • Vythilingam I, NoorAzian YM, Huat TC, Jiram AI, Yusri YM, Azahari AH, et al. Plasmodium knowlesi in humans, macaques and mosquitoes in peninsular Malaysia. Parasites and Vectors. 2008; 1(1):26. https://doi.org/10.1186/17563305-1-26. PMid: 18710577, PMCid: PMC2531168.

  • Singh B, Daneshvar C. Plasmodium knowlesi malaria in Malaysia. Medical Journal Malaysia. 2010; 65(3):166-172.

  • Barber BE, William T, Jikal M, Jilip J, Dhararaj P, Menon J, et al. Plasmodium knowlesi malaria in children. Emerging Infectious Disease. 2011; 17(5):814. https://doi.org/10.3201/eid1705.101489. PMid: 21529389, PMCid: PMC3321776.

  • Grigg MJ, William T, Dhanaraj P, Menon J, Barber BE, von Seidlein L, et al. A study protocol for a randomised open-label clinical trial of artesunate-mefloquine versus chloroquine in patients with non-severe Plasmodium knowlesi malaria in Sabah, Malaysia (ACT KNOW trial). British Medical Journal Open. 2014; 4(8):e006005. https://doi.org/10.1136/bmjopen-2014-006005. PMid: 25138814, PMCid: PMC4139630.

  • Fatih FA, Staines HM, Siner A, Ahmed MA, Woon LC, Pasini EM, et al. Susceptibility of human Plasmodium knowlesi infections to anti-malarials. Malaria Journal. 2013; 12(1):425. https://doi.org/10.1186/1475-2875-12425. PMid: 24245918, PMCid: PMC3874596.

  • Le Manach C, Scheurer C, Sax S, Schleiferböck S, Cabrera DG, Younis Y, et al. Fast in vitro methods to determine the speed of action and the stage-specificity of anti-malarials in Plasmodium falciparum. Malaria Journal. 2013; 12:424. https://doi.org/10.1186/1475-2875-12-424. PMid: 24237770, PMCid: PMC3842807.

  • Sowunmi A, Adewoye EO, Gbotsho GO, Happi CT, Sijuade A, Folarin OA, et al. Factors contributing to delay in parasite clearance in uncomplicated falciparum malaria in children. Malaria Journal. 2010; 9(1):53. https://doi.org/10.1186/1475-2875-9-53. PMid: 20156350, PMCid: PMC2834701.

  • Ariffin NM, Islahudin F, Kumolosasi E, Makmor-Bakry M. A clinical tool to predict Plasmodium vivax recurrence in Malaysia. BMC Infectious Disease. 2017; 17(1):759. https://doi.org/10.1186/s12879-017-2868-9. PMid: 29216842, PMCid: PMC5721364.

  • Woodrow CJ, Haynes RK, Krishna S. Artemisinins. Postgraduate Medical Journal. 2005; 81:71-78. https://doi.org/10.1136/pgmj.2004.028399. PMid: 15701735, PMCid: PMC1743191.

  • Gonçalves BP, Huang CY, Morrison R, Holte S, Kabyemela E, Prevots DR, et al. Parasite burden and severity of malaria in Tanzanian children. New England Journal of Medicine. 2014; 370(19):1799-1808. https://doi.org/10.1056/NEJMoa1303944. PMid: 24806160, PMCid: PMC4091983.

  • Choge JK, Ng’Wena GM, Akhwale W, Koech J, Ngeiywa MM, Oyoo-Okoth E, et al. Symptomatic malaria diagnosis overestimate malaria prevalence, but underestimate anaemia burdens in children: Results of a follow up study in Kenya. BMC Public Health. 2014; 14(1):332. https://doi.org/10.1186/1471-2458-14-332. PMid: 24712340, PMCid: PMC3996101.

  • Rawshan AB, Er A, Raja D, Pereira JJ. Malaria and climate change: Discussion on economic impacts. American Journal of Environmental Science. 2011; 7(1):73-82. https://doi.org/10.3844/ajessp.2011.73.82.

  • Mia MS, Begum RA, Er AC, Abidin RD, Pereira JJ. Burden of malaria at household level: A baseline review in the advent of climate change. Journal of Environmental Science and Technology. 2012; 5(1):1-5. https://doi.org/10.3923/jest.2012.1.15.

  • Fornace KM, Abidin TR, Alexander N, Brock P, Grigg MJ, Murphy A, et al. Association between landscape factors and spatial patterns of Plasmodium knowlesi infections in Sabah, Malaysia. Emerging Infectious Disease. 2016; 22(2):201. https://doi.org/10.3201/eid2202.150656. PMid: 26812373, PMCid: PMC4734530.


Abstract Views: 194

PDF Views: 99




  • Determinants of Parasite Clearance Time among Plasmodium knowlesi Patients in Malaysia

Abstract Views: 194  |  PDF Views: 99

Authors

Kien Seang Kwong
Quality Management of Medicine, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur − 50300, Malaysia
Farida Islahudin
Quality Management of Medicine, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur − 50300, Malaysia
ChooYai Wen
Department of Pharmacy, Hospital Kuala Lipis, 27200 Kuala Lipis, Pahang, Malaysia, Malaysia

Abstract


Plasmodium (P.) knowlesi infection was only recently discovered in 2004, and since then the number of cases has increased each year. As such, there is still a need to understand the clinical management of P. knowlesi infection to ensure control of the disease. Therefore, this work was performed to determine factors that affect the clinical outcome of P. knowlesi infected patients. A cross-sectional study from 2012 to 2016 was conducted in Hospital Kuala Lipis, Pahang, Malaysia. The main clinical outcome was parasite clearance. A total of 72 P. knowlesi patients were included, which were mostly male (n=56, 77.80%), with a mean age of 37.39±14.61 years. Fifty-six patients (77.80%) were prescribed with artemisinin-based antimalarial following diagnosis, while the remaining patients (n=16, 22.20%) were treated with chloroquine. The length for parasite clearance of P. knowlesi was 4(4-5) days [(median (IQR)]. Factors that affect the primary outcome of the study (>4 days for parasite clearance) was then determined. A multivariate logistic regression demonstrated that significant predictors of parasite clearance were initial parasite levels and number of symptoms (χ2=11.97, df(69), P=0.003). Those with an initial parasite count of > 2 400/uL were 4.8 times more likely to take > 4 days for parasite clearance (P=0.02). Having < 4 symptoms increased the odds of > 4 days for parasite clearance by 0.14 times (P=0.02). This study shows the need to closely monitor patients with higher initial parasite counts (> 2400/uL) and patients with > 4 symptoms associated with P. knowlesi infection, to ensure appropriate treatment is administered.


Keywords


Clinical Outcome, Malaria, Parasite, Plasmodium knowlesi

References





DOI: https://doi.org/10.18311/ajprhc%2F2020%2F25905